GlobeNewswire

AuX Labs Secures $4M to Commercialize Precision Fermentation Cheese Platform
21/04/2026
Funding will accelerate the launch of a scalable, precision-fermented dairy protein technology that performs like traditional cheese TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- AuX Labs, a food technology company using [...]
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
21/04/2026
Transaction expected to approximately triple NEXGEL’s annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified suite of 6 established [...]
Brain Cancer Canada Marks Brain Cancer Awareness Month in May with National Landmark Lightings, Community Events, New Research Investments, and a Call to Action
21/04/2026
Awareness events Research grant awards Gala for Brain Cancer Research with Catherine Wreford and Dr. Cynthia Hawkins TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), the only national charity [...]
Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call
21/04/2026
DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter 2026 financial [...]
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
21/04/2026
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been [...]
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
21/04/2026
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical [...]
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
21/04/2026
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution
21/04/2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
21/04/2026
Expansion Adds to Growing Global Trial Footprint Patient Screening and Enrollment Expected to Begin in Q2 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), [...]
Celularity Announces Closing of Transaction with NexGel
21/04/2026
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously [...]
Milestone Scientific Inc. Completes $2.15 Million Private Placement
21/04/2026
Financing Strengthens Balance Sheet and Supports Commercial Growth Strategy; Backed by Long-Term Investors Including CEO and Chairman of the Board ROSELAND, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific [...]
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
21/04/2026
· Approval by the Danish Medicines Agency (DKMA) for enrolling patients in Denmark follows the recently announced FDA clearance to initiate the Phase 2b study in the United States. Nes-Ziona, Israel, April 21, 2026 ( [...]
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
21/04/2026
PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that [...]
Cristcot Announces FDA Acceptance of NDA for Next-Generation Hydrocortisone Acetate (ngHCA) for Treatment of Ulcerative Colitis (UC) of the Rectum
21/04/2026
-- Prescription Drug User Fee Act (PDUFA) target date of October 2026 -- -- Submission supported by CESSA Phase 3 trial results demonstrating statistically significant rates of clinical remission in patients with UC of [...]
BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Inflammatory Disease
21/04/2026
Collaboration aims to identify biological signatures and patient subpopulations most likely to benefit from BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases [...]
Spur Therapeutics To Present New Clinical Data on FLT201 for Gaucher Disease during the IWGGD 2026 Symposium
21/04/2026
LONDON, April 21, 2026 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced the presentation of new insights from its Phase 1/2 GALILEO-1 and GALILEO-2 trials of avigbagene parvec (FLT201), its investigational gene [...]
InnovAge to Announce Fiscal Third Quarter 2026 Financial Results and Host Conference Call Tuesday, May 5, 2026
21/04/2026
DENVER, April 21, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
21/04/2026
PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open [...]
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
21/04/2026
- The Ministry of Health has set a 180-working-day review period for the MAA - - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C., April 21, 2026 (GLOBE [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum